Predictive Oncology Inc
NASDAQ:POAI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its Industry Average (18.7), the stock would be worth $-43.42 (892% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -2.4 | $5.48 |
0%
|
| Industry Average | 18.7 | $-43.42 |
-892%
|
| Country Average | 16.7 | $-38.78 |
-808%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Predictive Oncology Inc
NASDAQ:POAI
|
18.6m USD | -2.4 | -0.2 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.8T JPY | 36.7 | 39.1 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
59.4B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
28.9B CHF | 17.4 | 37.2 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
93.1B DKK | 16.3 | 23.1 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.2B USD | 20.3 | 32.1 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.3B GBP | 15.1 | 32.5 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | 36.3 | -15.6 | |
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
37.8B CNY | 19.3 | 22.2 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
879B JPY | 20.5 | 49.7 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
37.3B CNY | 23.5 | 22.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.7 |
| Median | 16.7 |
| 70th Percentile | 23.6 |
| Max | 3 178 983.5 |
Other Multiples
Predictive Oncology Inc
Glance View
Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal and associated products. The company is headquartered in Eagan, Minnesota and currently employs 30 full-time employees. The company went IPO on 2009-12-18. The firm provides predictive models of tumor drug response that are used to improve clinical outcomes for patients. The company operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment includes clinical testing and contract research services that include the application of AI. zPREDICTA specializes in organ-specific disease models that provide 3D reconstruction of human tissues, accurately representing each disease state and mimicking drug response, enabling accurate testing of anticancer agents. The Soluble segment provides services using a self-contained, automated system that conducts throughput, self-interaction chromatography screens using additives and excipients commonly included in protein formulations, resulting in soluble and physically stable formulations for biologics. The Skyline segment consists of the STREAMWAY System product sales.
